Enzalutamide Improves Quality of Life in Patients with Metastatic Prostate Cancer After Chemotherapy

Share this content:

the Cancer Therapy Advisor take:

Enzalutamide is effective in improving health-related quality of life outcomes in men with progressive metastatic castration-resistant prostate cancer (mCRPC) after docetaxel-based chemotherapy, according to a study published in Annals of Oncology.

In an additional analysis of the 25-week randomized, placebo-controlled AFFIRM trial, researchers examined changes in Functional Assessment of cancer Therapy-Prostate (FACT-P) scores in 938 patients randomized to enzalutamide (160 mg/day) or placebo. FACT-P scores were gathered prior to randomization and at set intervals throughout the study.

Longitudinal changes were measured from baseline to 25 weeks using a mixed effects model for repeated measures (MMRM), with a secondary pattern mixture model (PMM). Cumulative distribution function (CDF) plots were applied for missing data.

The researchers found that after 25 weeks, mean FACT-P scores decreased by 1.52 in the enzalutamide group compared to 13.73 with placebo.

Additionally, significant treatment differences favoring enzalutamide were apparent in all FACT-P subscales and indices in both MMRM and PMM models. CDF plots favored the use of enzalutamide across all response levels for FACT-P scores.

Enzalutamide Improves Quality of Life in Patients with Metastatic Prostate Cancer After Chemotherapy
Enzalutamide improves quality of life outcomes in progressive mCRPC.

This study aims to present longitudinal changes in Functional Assessment of Cancer Therapy–Prostate (FACT–P) scores during 25–week treatment with enzalutamide or placebo in men with progressive metastatic castration–resistant prostate cancer (mCRPC) after chemotherapy in the AFFIRM trial.

In men with progressive mCRPC after docetaxel–based chemotherapy, enzalutamide is superior to placebo in health–related quality of life outcomes, regardless of analysis model or threshold selected for meaningful response.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs